Why the study?
Does monitoring serum quinidine concentration improve the conversion of chronic atrial fibrillation and reduce myocardial toxicity compared to dosing alone?
Does monitoring serum quinidine concentration improve the conversion of chronic atrial fibrillation and reduce myocardial toxicity compared to dosing alone?
Monitoring serum quinidine concentration rather than relying on dose alone may optimize the conversion of chronic atrial fibrillation while minimizing myocardial toxicity.
Answers are grounded in this paper and cite their sources.
Serum quinidine monitoring may limit myocardial toxicity given marked interindividual variability; leaves open whether it improves chronic AF conversion versus dose alone.
Opinion differs greatly about the value and risk of quinidine. The present communication attempts to demonstrate that more rational use of quinidine is possible by emphasis on serum quinidine concentration rather than on dose alone. Conversion of chronic atrial fibrillation and the appearance of myocardial toxicity are related more closely to the concentration of quinidine in the blood than to the dose. The serum concentration achieved with equal doses of the drug varied strikingly in different individuals; myocardial toxicity was infrequent at levels less than 6.0 /g=m/g./ml. and increased proportionately as this level was exceeded. These levels could not always be predicted from the dose given.
No takes yet. Share an insight, caveat, or question.
Sokolow et al. (1956) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: